ACOX1

Peroxisomal acyl-coenzyme A oxidase 1 · Q15067 · ACOX1 on Sugi Atlas →

2,319 patent compounds predicted against ACOX1, 1,993 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL4942072	0.52	2/20
Hydralazine (SCHEMBL7810)	1.00	1/20
Masitinib (SCHEMBL717239)	1.00	1/20
Alectinib (SCHEMBL896753)	1.00	1/20
Hydralazine (SCHEMBL3995896)	1.00	1/20
Hydralazine (SCHEMBL36271)	0.96	1/20
Hydralazine (SCHEMBL1173534)	0.96	1/20
Masitinib (SCHEMBL1096348)	0.94	1/20
Masitinib (SCHEMBL2297143)	0.94	1/20
Hydralazine (SCHEMBL1650561)	0.93	1/20
SCHEMBL3301373	0.91	1/20
SCHEMBL896761	0.90	1/20
Hydralazine (SCHEMBL2780318)	0.89	1/20
SCHEMBL717173	0.88	1/20
SCHEMBL898391	0.88	1/20
SCHEMBL717184	0.87	1/20
SCHEMBL898293	0.87	1/20
SCHEMBL897920	0.87	1/20
SCHEMBL898091	0.87	1/20
SCHEMBL4828703	0.86	1/20

Clinical trials — most relevant to ACOX1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Omega 3 and Ischemic Stroke; Fish Oil as an Option	PHASE4	UNKNOWN
Betaine and Peroxisome Biogenesis Disorders	PHASE3	COMPLETED
Effect of Bezafibrate on Muscle Metabolism in Patients With Fatty Acid Oxidation Defects	PHASE2	COMPLETED
Acetylcarnitine and Insulin Sensitivity	PHASE2	COMPLETED
Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease	PHASE2	COMPLETED
The Effects of Coenzyme A Combined With Abiraterone on Patients With CRPC	PHASE1/PHASE2	UNKNOWN
Autologous Hematopoietic Stem Cell Gene Therapy for Metachromatic Leukodystrophy and Adrenoleukodystrophy	PHASE1/PHASE2	UNKNOWN
A Study of Bezafibrate in Mitochondrial Myopathy	PHASE2	COMPLETED
The Effects of Coenzyme A on Serum Lipids in Patients With Hyperlipidemia	PHASE2	COMPLETED
Liver Positron Emission Tomography (PET) Study of Non Alcoholic Fatty Liver Disease	EARLY_PHASE1	COMPLETED
Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study	nan	COMPLETED
Study of Protein Translocation in Patients With Beta-Oxidation Disorders	nan	COMPLETED
Lifestyle Intervention in Preparation for Pregnancy (LIPP)	nan	COMPLETED
High Fat Diet for Cardiac Metabolic Reprogramming	nan	RECRUITING
Evaluation of a New Strategy for the Diagnosis of Peroxisomal Diseases	nan	COMPLETED
Fatty Acid Oxidation Defects and Insulin Sensitivity	nan	COMPLETED
Effects of Parenteral L-carnitine Supplementation in Premature Neonates	nan	COMPLETED
Hepatic Energy Fluxes in NASH and NAS Patients	nan	ACTIVE_NOT_RECRUITING
Re-energize With Nutrition, Exercise and Weight Loss	nan	COMPLETED
Evaluate the Effort Test as a Therapeutic Monitoring Tool in Acute Rhabdomyolyses	nan	COMPLETED
Effect of Omega-3 Fatty Acids Supplementation on Hypertriglyceridemia in Pediatric Patients With Obesity.	nan	COMPLETED
Exercise Intolerance Study in Long Chain Fatty Acid Oxidation Disorders	nan	RECRUITING
Nutritional Therapy of the Deficits of Oxidation Mitochondrial of the Fatty Acids	nan	COMPLETED
Promotion of Weight Management	nan	ACTIVE_NOT_RECRUITING
Systemic Biomarkers of Brain Injury From Hyperammonemia	nan	RECRUITING
Genetics in the Effect of Caffeine on Fat Oxidation	nan	COMPLETED
Effect of a PPAR-Alpha Agonist on the Age Related Changes in Myocardial Metabolism and Mechanical Function	nan	UNKNOWN
Expanded Access to Triheptanoin	nan	AVAILABLE
Effect of SGLT2 Inhibitors on NAFLD in Type 2 Diabetic Patients with Diabetic Nephropathy	nan	NOT_YET_RECRUITING
11C-Acetate PET/CT Non-FDG-Avid Tumors	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a ACOX1 binder may also engage these)

Protein	Name	Similarity
P07872	—	1.000	P07872 →
Q8HYL8	—	1.000	Q8HYL8 →
Q9Z1N0	—	1.000	Q9Z1N0 →
O62137	—	1.000	O62137 →
Q3SZP5	—	1.000	Q3SZP5 →
Q5RC19	—	1.000	Q5RC19 →
O65202	—	1.000	O65202 →
Q9R0H0	—	1.000	Q9R0H0 →
O65201	—	1.000	O65201 →
O62139	—	0.999	O62139 →
O62138	—	0.997	O62138 →
Q9QXD1	—	0.997	Q9QXD1 →
Q9ZQP2	—	0.996	Q9ZQP2 →
Q7KML2	—	0.996	Q7KML2 →
O74934	—	0.995	O74934 →
P97562	—	0.995	P97562 →
P0CZ23	—	0.995	P0CZ23 →
Q9LMI7	—	0.995	Q9LMI7 →
Q20992	—	0.994	Q20992 →
P08790	—	0.994	P08790 →
P34355	—	0.994	P34355 →
Q9EPL9	—	0.993	Q9EPL9 →
Q99424	—	0.993	Q99424 →
Q6BRD5	—	0.993	Q6BRD5 →
O62140	—	0.993	O62140 →
ACOX3	Peroxisomal acyl-coenzyme A oxidase 3	0.991	landscape →
Q63448	—	0.991	Q63448 →
O64894	—	0.991	O64894 →
O74936	—	0.990	O74936 →
O02767	—	0.990	O02767 →